RFA-NS-21-017: Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make one award worth $2.0 million in total. Applications closed on March 15, 2021.
From the official notice on Grants.gov, last changed January 6, 2021. Checked November 7, 2026.
- Total funding$2.0 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$2.1 million
- Typical project length2 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-NS-21-017 were run by National Institute of Neurological Disorders and Stroke (NINDS, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-21-017 in the NIH Guide.
Key dates
| Posted | January 6, 2021 |
|---|---|
| Deadline | March 15, 2021 |
| Archived by Grants.gov | April 20, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This FOA seeks applications to perform single nucleus RNA sequencing (snRNA seq) and whole genome sequencing (WGS) in post-mortem brain tissue from 100 patients with PD and normal controls for the Accelerating Medicine Partnership in Parkinson's Disease (AMP PD). Applicants will be expected to have access to high quality brain tissue and perform sequencing in four separate brain regions, including some regions known to be affected by Parkinson's Disease (PD) and at least one region known to be relatively spared. It is intended that all sequencing data and any available pre-mortem clinical data will be broadly shared with the research community through the AMP PD Knowledge Portal.
Funded under RFA-NS-21-017 so far
NIH funded 1 project under RFA-NS-21-017 in fiscal 2021, at 1 institution. The median yearly award was $2.1 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Single-nucleus transcriptome profiling across multiple brain regions in Parkinson's Disease | Icahn School of Medicine at Mount Sinai | 2021 | $2.1 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-21-017 still open?
No. It closed on March 15, 2021.
Who can apply for Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed)?
Closed March 15, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $2.0 million in total for one award.
Who has been funded under RFA-NS-21-017?
NIH RePORTER lists 1 project funded under RFA-NS-21-017 in fiscal 2021, at 1 institution.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)